-
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US09077A1060 |
| Industry | Biotechnology |
| Sector | Healthcare |
| PE Ratio | None |
|---|---|
| Beta | -0.25 |
| Market Cap | 107M |
| Target Price | 18.25 |
| Dividend Yield | None |
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States. It's lead product candidate icovamenib, an orally bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle control, apoptosis, and DNA damage repair. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in San Carlos, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for BMEA using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025